normative

Age-Stratified Trials Would Yield More Safety Data

Running separate randomized trials by age cohort (nursing homes powered for mortality, 60-80 for severe disease, younger groups for transmission) rather than one 18-100 study would have allowed younger cohorts' trials to run longer without crossover, preserving the ability to detect waning efficacy and safety signals—feasible because supply constraints meant the elderly got the vaccine first anyway.

normativepending

Speaker

Vinay Prasad

Evidence Quote

“when you start to break it out by age groups in multiple studies, studies can halt at different times. We have one study and the moment it halts, everybody on the control arm gets the vaccine. So, essentially, detecting safety signals is a wash.”

Source

The Good, the Bad, and the Ugly of the Covid Vaccine (with Vinay Prasad)— EconTalk
Created: 6/13/2026, 12:19:32 AM

Your notes

Loading notes...